Results 161 to 170 of about 179,985 (317)
Pair‐wise comparison of the CellSearch and FETCH enrichment technologies for circulating tumor cells (CTCs) from metastatic breast, prostate, and small cell lung cancer patients shows an increased capture of CTCs using FETCH enrichment. The clinical implementation of circulating tumor cells (CTCs) as a predictive tool for therapy efficacy in the ...
Michiel Stevens +6 more
wiley +1 more source
Integrating interstitial lung abnormality detection into lung cancer screening: a mixed methods approach for care pathway development. [PDF]
Kim DH +5 more
europepmc +1 more source
We identify USP29 as the only DUB mirroring CA9 expression, a marker of hypoxia and HIF pathway activation associated with PCA aggressiveness. USP29 stabilizes HIF‐1α and HIF‐2α via a noncanonical mechanism that is independent of PHD/pVHL activity yet relies on proteasomal regulation, establishing USP29 as a previously unrecognized regulator of hypoxic
Amelie S Schober +16 more
wiley +1 more source
Exposing the Rad to Radionuclide: Why Early Education in Theranostics Is Important to Radiologists
Andy Ho, Nicola Luppino, Lincoln J. Lim
doaj +1 more source
Survey on Inter- and Intra-Observer Variations of the Ultrasound Assessment of Dog Pancreases. [PDF]
Turner RBS +3 more
europepmc +1 more source
A transformer-based deep learning algorithm for diagnosing spinal infections on axial non-contrast computed tomography images: a dual-center retrospective study. [PDF]
Yu D +8 more
europepmc +1 more source
Finding novel vulnerabilities of hypomorphic BRCA1 alleles
Synthetic lethality screens performed to identify novel vulnerabilities often model complete gene loss, thereby overlooking patient‐derived hypomorphic mutations. In this study, we have performed genome‐wide CRISPR screens on BRCA1 hypomorphic mutations, showing BRCA1I26A behaves like wild‐type, while BRCA1R1699Q mimics deficiency. Furthermore, we have
Anne Schreuder +10 more
wiley +1 more source
Artificial Intelligence for Mammography Ready for the Real-World: Turning Promise Into Reality. [PDF]
Yoon JH, Kim EK.
europepmc +1 more source
Many patients with urothelial cancer do not benefit from treatment with pembrolizumab, while at risk of severe side effects. Changes in the levels of circulating tumor DNA early during treatment, measured by a simple and affordable assay that can be easily implemented in the clinic, can be used as a prognostic tool to identify these patients.
Youssra Salhi +14 more
wiley +1 more source

